Overcoming the delivery bottleneck of gene and RNA therapeutics with FDA-cleared gold nanoparticle (AuNP) carriers and cell-specific aptamers.
Partner With UsEnables systemic delivery to key intracellular compartments with high payload capacity (approx. 100 payloads per particle).
US FDA Phase 1 approval history for baseline carriers in 2018, backed by comprehensive in-house GLP safety validation and established NOAEL.
Utilizes cell-specific aptamers (ApDC) for targeted cell delivery while achieving effective liver/spleen de-targeting.
| Pipeline | Modality | Indication | Development Stage | L/O Target |
|---|---|---|---|---|
| NES-TRD1 | ASO / siRNA / shRNA | Pancreatic (1st), Colorectal, NSCLC (KRAS-G12D) | Preclinical (2027 IND) | 2027 ($200M+) |
| NES-GLS | Glucose-sensing DNA | Type 1 Diabetes & Severe Type 2 | Preclinical (2027 IND) | 2027 ($350M+) |
| AuGenedit | CRISPR / Cas9 + TfR1 aptamer | DM1 (Myotonic Dystrophy Type 1) | Preclinical (2028 IND) | 2028 ($350M+) |
| AuX-ASOcov | RNase H ASO | COVID-19 (Broad variant coverage) | Preclinical → 2027 IND | 2027 ($700M+) |
| AuX-mRNA-V1 | mRNA Vaccine Platform | COVID-19 / Flu / Cancer (Room-temp storage) | IND Filing Complete | 2026 (L/O in progress) |
Founder & CEO
Professor of Life Science, Chung-Ang University. 35+ years in RNA biology with 150+ peer-reviewed publications.
CTO
Professor, College of Pharmacy, Chung-Ang University. Expert in Pharmacology, Toxicology, and MFDS Safety Review Committee member.
Scientific Advisory Board
Professor, Stanford University. Pioneer of recombinant DNA technology and co-founder of Genentech.
Interested in partnering, licensing opportunities, or Series A participation?
Email: info@nesbiotech.com | jhyeom@nesbiotech.com
Website: www.nesbiotech.com